Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract 3502: Preclinical development of an mRNA-encoded T cell engager targeting Glypican-3 with tissue- and tumor-specific enrichment in hepatocellular carcinoma

Yan Huang, Shaoli Liu, Xiaoju Zhang, Bingxu Zhang, Hongya Han, Andong Liu, Xiaoyun Ma, Wei Xu

Cancer Res (2025) 85 (8_Supplement_1): 3502.

https://doi.org/10.1158/1538-7445.AM2025-3502

Published: 21 April 2025

View articletitled, Abstract 3502: Preclinical development of an mRNA-encoded T cell engager targeting Glypican-3 with tissue- and tumor-specific enrichment in hepatocellular carcinoma

Journal Articles

Abstract 1567: GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation

Jiao Jiao, Yingjie Sun, Jiaxing Wang, Liming Che, Menghan Cui, Wenjie Shao, Hairui Yuan, Yan Huang, Nannan Zhai, Yuling Tang, Xiaomei Zheng, Siyao Li

Cancer Res (2025) 85 (8_Supplement_1): 1567.

https://doi.org/10.1158/1538-7445.AM2025-1567

Published: 21 April 2025

View articletitled, Abstract 1567: GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation

Journal Articles

Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

Yunpeng Yang, Yuanyuan Zhao, Wenfeng Fang, Yan Huang, Yaxiong Zhang, Yi Ba, Zhen Wang, Chao Deng, Desheng Hu, Wei Wang, Guiling Li, Suxia Luo, Zhichao Fu, Haisheng Zhu, Huili Wang, Shiwei Zhao, Tao Li, Charles Cai, Li Zhang

Cancer Res (2024) 84 (7_Supplement): CT227.

https://doi.org/10.1158/1538-7445.AM2024-CT227

Published: 05 April 2024

View articletitled, Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

Journal Articles

Abstract 1999: DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma

Qing-Jie Li, Xue-Liang Fang, Ying-Qin Li, Jia-Yi Lin, Cheng-Long Huang, Shi-Wei He, Sheng-Yan Huang, Jun-Yan Li, Sha Gong, Kai-Lin Chen, Na Liu, Jun Ma, Yin Zhao, Ling-Long Tang

Cancer Res (2024) 84 (6_Supplement): 1999.

https://doi.org/10.1158/1538-7445.AM2024-1999

Published: 22 March 2024

View articletitled, Abstract 1999: DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma

Journal Articles

Abstract 3272: PJA1 inhibits docetaxel-induced pyroptosis and results in chemoresistance in nasopharyngeal carcinoma

Na Liu, Ying-Qing Li, Sheng-Yan Huang

Cancer Res (2024) 84 (6_Supplement): 3272.

https://doi.org/10.1158/1538-7445.AM2024-3272

Published: 22 March 2024

View articletitled, Abstract 3272: PJA1 inhibits docetaxel-induced pyroptosis and results in chemoresistance in nasopharyngeal carcinoma

Journal Articles

Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Kankan Cao, Guodong Zhang, Moran Yang, Yiying Wang, Mengdi He, Chen Zhang, Yan Huang, Jiaqi Lu, Haiou Liu

Cancer Res (2023) 83 (13): 2171–2186.

https://doi.org/10.1158/0008-5472.CAN-22-3260

Published: 05 July 2023

View articletitled, Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Includes: Supplementary data

Journal Articles

Abstract 3089: XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies

Cancer Res (2023) 83 (7_Supplement): 3089.

https://doi.org/10.1158/1538-7445.AM2023-3089

Published: 04 April 2023

View articletitled, Abstract 3089: XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies

Journal Articles

Abstract CT520: The safety summary of the phase 1a/b trial of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced malignant tumors

Li Zhang, Hongyun Zhao, Yan Huang, Wenfeng Fang, Yuxiang Ma, Yang Zhang, Xiaoli Wei, Yanhua Yang, Wei Yang, Furong Liu, Zuan Lin, Jianing Li, Qianwen Liu, Benyan Zou, Kunlun Liao, qun Liu

Cancer Res (2022) 82 (12_Supplement): CT520.

https://doi.org/10.1158/1538-7445.AM2022-CT520

Published: 15 June 2022

View articletitled, Abstract CT520: The safety summary of the phase 1a/b trial of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced malignant tumors

Journal Articles

Abstract CT119: Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product

Li Zhang, Hongyun Zhao, Yuxiang Ma, Yan Huang, Yang Zhang, Xiaoli Wei, Yanhua Yang, Wei Yang, Furong Liu, Zhuan Lin, Jianing Li, Wenfeng Fang, Qianwen Liu, Benyan Zou, Kunlun Liao, Liuqun Liu

Cancer Res (2021) 81 (13_Supplement): CT119.

https://doi.org/10.1158/1538-7445.AM2021-CT119

Published: 01 July 2021

View articletitled, Abstract CT119: Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product

Journal Articles

Abstract 579: Ensartinib (X-396), a novel ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation and expansion study

Hongyun Zhao, Yuxiang Ma, Yang Zhang, Shaodong Hong, Wenfeng Fang, Yunpeng Yang, Jianjin Huang, Jing Zhao, Yan Huang, Lieming Ding, Li Mao, Giovanni Selvaggi, Li Zhang

Cancer Res (2020) 80 (16_Supplement): 579.

https://doi.org/10.1158/1538-7445.AM2020-579

Published: 15 August 2020

View articletitled, Abstract 579: Ensartinib (X-396), a novel ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation and expansion study

Journal Articles

Abstract 707: Combinatorial assessment of ctDNA release and mutational burden predicts clinical outcome from anti-PD-(L)1 therapies in non-small-cell lung cancer

Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Huaqiang Zhou, Fufeng Wang, Hua Bao, Ao Wang, Xue Wu, Shaodong Hong, Yunpeng Yang, Yan Huang, Hongyun Zhao, Yang W. Shao, Li Zhang

Cancer Res (2020) 80 (16_Supplement): 707.

https://doi.org/10.1158/1538-7445.AM2020-707

Published: 15 August 2020

View articletitled, Abstract 707: Combinatorial assessment of ctDNA release and mutational burden predicts clinical outcome from anti-PD-(L)1 therapies in non-small-cell lung cancer

Journal Articles

Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers

Cancer Res (2017) 77 (13_Supplement): 4144.

https://doi.org/10.1158/1538-7445.AM2017-4144

Published: 01 July 2017

View articletitled, Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers

Journal Articles

Abstract 798: Label-free enrichment and detection of circulating tumor cells in metastatic breast cancer patients show 82% of cohorts have detectable targets

Yu-Jen Chang, Chen-Lin Chen, Wei-Fan Hsu, Meng-Ze Li, Wei-Yuan Ma, Ken-Chao Chen, Guan-Syuan Huang, Wai-Sang Wong, Jhan-Yu Syu, Thomas, Yo-Yan Huang, Ching-Hung Lin, Andrew M. Wo, Chiun-Sheng Huang

Cancer Res (2017) 77 (13_Supplement): 798.

https://doi.org/10.1158/1538-7445.AM2017-798

Published: 01 July 2017

View articletitled, Abstract 798: Label-free enrichment and detection of circulating tumor cells in metastatic breast cancer patients show 82% of cohorts have detectable targets

Journal Articles

Abstract 3873: Improving the effectiveness of chemotherapy by combining compounds that suppress drug-induced microsatellite instability

Christina L. Chang, Li-Yan Huang, Chang-Lin Wu, Jhih-Ying Chi

Cancer Res (2015) 75 (15_Supplement): 3873.

https://doi.org/10.1158/1538-7445.AM2015-3873

Published: 01 August 2015

View articletitled, Abstract 3873: Improving the effectiveness of chemotherapy by combining compounds that suppress drug-induced microsatellite instability

Journal Articles

miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer

Yan Zhang, Li-Xu Yan, Qi-Nian Wu, Zi-Ming Du, Jing Chen, Ding-Zhun Liao, Ma-Yan Huang, Jing-Hui Hou, Qiu-Liang Wu, Mu-Sheng Zeng, Wen-Lin Huang, Yi-Xin Zeng, Jian-Yong Shao

Cancer Res (2011) 71 (10): 3552–3562.

https://doi.org/10.1158/0008-5472.CAN-10-2435

Published: 15 May 2011

View articletitled, miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract 4625: A biotin-label-based antibody array for high-content profiling of protein expression

Ruochun Huang, Weidong Jiang, Jean Yang, Ying Qing Mao, Ying Zhang, Weiming Yang, Dongzi Yang, Brett Burkholder, Rani Yan Huang, Ruo-Pan Huang

Cancer Res (2010) 70 (8_Supplement): 4625.

https://doi.org/10.1158/1538-7445.AM10-4625

Published: 15 April 2010

View articletitled, Abstract 4625: A biotin-label-based antibody array for high-content profiling of protein expression

Journal Articles

Abstract 3666: Follicle-stimulating hormone inhibits apoptosis and autophagy in ovarian cancer cells by activating survivin and Rab25

Yingtao Liu, Yan Huang, Hongyan Jin, Kwai Wa Cheng, Yiling Lu, Yinhua Yu, Youji Feng

Cancer Res (2010) 70 (8_Supplement): 3666.

https://doi.org/10.1158/1538-7445.AM10-3666

Published: 15 April 2010

View articletitled, Abstract 3666: Follicle-stimulating hormone inhibits apoptosis and autophagy in ovarian cancer cells by activating survivin and Rab25

Journal Articles

Abstract #894: Lapatinib could reverse ABCB1 and ABCG2 mediated-multidrug resistance in Vitro, ex-vivo and in Vivo but increase exposure of chemotherapeutic agent

Chun-ling Dai, Yan-sheng Wang, Amit Tiwari, Chung-pu Wu, Xiao-dong Su, Si-rong Wang, Dong-geng Liu, Charles Ashby Jr., Yan Huang, Robert Robey, Yong-ju Liang, Li-ming Chen, Cheng-jun Shi, Suresh Ambudkar, Zhe-sheng Chen, Liwu Fu

Cancer Res (2009) 69 (9_Supplement): 894.

Published: 01 May 2009

View articletitled, Abstract #894: Lapatinib could reverse ABCB1 and ABCG2 mediated-multidrug resistance in Vitro, ex-vivo and in Vivo but increase exposure of chemotherapeutic agent

Journal Articles

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Chun-ling Dai, Amit K. Tiwari, Chung-Pu Wu, Xiao-dong Su, Si-Rong Wang, Dong-geng Liu, Charles R. Ashby, Jr., Yan Huang, Robert W. Robey, Yong-ju Liang, Li-ming Chen, Cheng-Jun Shi, Suresh V. Ambudkar, Zhe-Sheng Chen, Li-wu Fu

Cancer Res (2008) 68 (19): 7905–7914.

https://doi.org/10.1158/0008-5472.CAN-08-0499

Published: 30 September 2008

View articletitled, Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Includes: Supplementary data

Journal Articles

Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases

Thomas Kelly, Larry J. Suva, Yan Huang, Veronica MacLeod, Hua-Quan Miao, Ronald C. Walker, Ralph D. Sanderson

Cancer Res (2005) 65 (13): 5778–5784.

https://doi.org/10.1158/0008-5472.CAN-05-0749

Published: 01 July 2005

View articletitled, Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 3502: Preclinical development of an mRNA-encoded T cell engager targeting Glypican-3 with tissue- and tumor-specific enrichment in hepatocellular carcinoma

Abstract 1567: GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation

Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

Abstract 1999: DCAF7 acts as a scaffold to recruit USP10 for G3BP1 deubiquitylation and facilitates chemoresistance and metastasis in nasopharyngeal carcinoma

Abstract 3272: PJA1 inhibits docetaxel-induced pyroptosis and results in chemoresistance in nasopharyngeal carcinoma

Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Abstract 3089: XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies

Abstract CT520: The safety summary of the phase 1a/b trial of QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, for advanced malignant tumors

Abstract CT119: Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product

Abstract 579: Ensartinib (X-396), a novel ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation and expansion study

Abstract 707: Combinatorial assessment of ctDNA release and mutational burden predicts clinical outcome from anti-PD-(L)1 therapies in non-small-cell lung cancer

Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers

Abstract 798: Label-free enrichment and detection of circulating tumor cells in metastatic breast cancer patients show 82% of cohorts have detectable targets

Abstract 3873: Improving the effectiveness of chemotherapy by combining compounds that suppress drug-induced microsatellite instability

miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer

Abstract 4625: A biotin-label-based antibody array for high-content profiling of protein expression

Abstract 3666: Follicle-stimulating hormone inhibits apoptosis and autophagy in ovarian cancer cells by activating survivin and Rab25

Abstract #894: Lapatinib could reverse ABCB1 and ABCG2 mediated-multidrug resistance in Vitro, ex-vivo and in Vivo but increase exposure of chemotherapeutic agent

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only